successfully identified a surface marker specific for NKX2.1 + lung cells. These four reports [14] [15] [16] generated AFE in a manner similar to our original paper 1 . Wong et al. 18 used air-liquid interphase cultures to generate ciliated proximal airway cells as well, but they used a very different strategy to generate AFE. However, there were no data on efficiency and yield 18 . The protocol described here provides a quantitative and efficient system for generating predominantly distal lung and, to a lesser extent, airway epithelial cells.
Experimental design
An overview of the protocol is given in Figure 1 . The entire differentiation is conducted in defined serum-free conditions, although serum is used to inactivate trypsin at steps requiring trypsin passaging of the cells. Serum can be substituted with commercially available trypsin inhibitors. The first part involves stepwise, sequential induction of early lung progenitors (Steps 1-26). hPSCs are passaged on Matrigel-coated plates to deplete residual mouse embryonic fibroblasts (MEFs; Steps 1-6). Primitive streak (Steps 7-9) and subsequently DE (Steps 10-13) are induced using established protocols 21, 22 . AFE is then specified based on our previous protocol 1 , with modifications that specifically improve the yield of NKX2.1 + developmental lung bud progenitors (Steps 14-17; ref. 2) . More specifically, inhibition of BMP and TGF-β signaling for 24 h is followed by a 24-h inhibition of TGF-β and Wnt signaling. Subsequent lung field induction is achieved by activating Wnt, FGF, BMP and RA signaling (Steps [18] [19] [20] [21] [22] [23] [24] [25] [26] , pathways that are crucial for lung field specification in the mouse 19, [23] [24] [25] . The early lung progenitors generated by this protocol (between days 15 and 25) are capable of in vivo differentiation into the six types of lung and airway epithelial cells after transplantation under the kidney capsule of immunodeficient mice 2 . The second half of the protocol (Steps 27-30) describes the long-term differentiation of hPSC-derived lung progenitors in vitro into predominantly distal cells. This step is performed in the presence of Wnt and FGF signaling. Adding factors known to induce alveolar maturation 13, 26 at this stage leads to a strong enrichment of functional ATII cells in the culture 2 .
The cultures can be analyzed using several approaches, including transplantation under the kidney capsule of immunodeficient mice, quantitative RT-PCR (RT-qPCR), immunofluorescence (IF) and uptake and release of fluorescently labeled surfactant protein (SP)-B. Procedures for this are standard, and they are described in our original paper 2 . The antibodies used are shown in Table 1 . However, the use of appropriate controls is critical. We use undifferentiated hPSCs as controls for transplantation under the kidney capsule of immunodeficient NSG mice.
These cells give rise to a teratoma that contains cells from all three germ layers. In contrast, cells differentiated into lung progenitors only generate respiratory epithelium and mesoderm 2 . Controls for SP-B uptake are cells at d15 of differentiation, which do not express any markers of differentiated cells and do not take up SP-B. Positive controls for IF include human adult and fetal lung sections 2 . Negative controls for IF and qPCR are random differentiation of hPSCs induced by withdrawal of renewal factors, or hPSCs differentiated into alternative endodermal lineages using published strategies. We typically use differentiation into the hepatic lineage 27 as a control for IF and qPCR. We believe that such 'biological negative controls', i.e., related cells that do not express the markers of interest, should be used as controls for IF. These are frequently more helpful in differentiating nonspecific background signal from specific antibody signal, compared with immunoglobulin (isotype) controls or secondary-only controls.
Limitations
We have shown that after transplantation under the kidney capsule of immunodeficient NSG mice the progenitors generated in this protocol can generate both proximal airway and distal lung epithelial cells. However, during further in vitro differentiation according to our protocol, differentiation is clearly biased toward distal lung. Furthermore, we believe that the cultures are still at a fetal stage of development. Evidence supporting this notion includes the fact that although cells that express the basal cell marker p63 are present, these cells do not express nerve growth factor receptor (NGFR), a marker of adult basal cells 28 bipotential alveolar progenitors that arise during the saccular stage of alveolar development 29 . In contrast, we find apoptosis in areas with cells expressing airway markers. These findings explain the progressive bias of this model toward distal lung. Another limitation is that there is clear variability in the efficiency of this protocol across hESC and hiPSC lines, with purities of lung progenitors ranging from 70% to nearly 100%. This phenomenon is well established in the field [30] [31] [32] .
Finally, we are cognizant of the fact that for future clinical applications, hPSC lines that have not been in contact with any reagents derived from animals are required. This protocol may be the basis of future clinical protocols; however, clinical application will require many Good Manufacturing Practice (GMP) modifications, of which feeder-free culture of the hPSCs is only one. Longterm maintenance in the absence of feeders compromised DE induction for some hPSCs in our hands, and feeder-independent conditions that maintain hPSCs as competent for differentiation are not yet available. It is hoped that the recently identified methods to convert hESCs to 'ground state' or naive ESCs 33, 34 , similar to mouse ESCs, might solve this issue in the future. Fig. 1 ). Culture hPSCs in a 95% air/5% CO 2 tissue culture incubator. We use irradiated MEFs feeders, as we found that this culture system best maintains the endoderm potential of the cells. Plate feeders at a density of ~20,000-25,000 cells per cm 2 into gelatincoated six-well tissue culture plates, and use them ~24 h after plating for hPSC passaging and thawing. Thaw hPSCs at a higher density than that used for passaging. We thaw RUES2 cells at a density of ~20,000-25,000 cells per cm 2 . It is optional to add Y-27632 to the hPSC medium. We thaw hiPSCs at a similar density of ~20,000-25,000 cells per cm 2 , but in the presence of 10 mM Y-27632 for 24 h. Passage hPSCs with Accutase/EDTA every 4 d onto the feeders using a stem cell passaging tool. We passage RUES2 cells at a density of ~7,000-9,000 cells per cm 2 without ROCK inhibitor Y-27632, and most iPSCs at a density of ~10,000-12,000 cells per cm 2 in the presence of 10 mM Y-27632 for 24 h, respectively. Change the hPSC medium daily. For rapidly growing hPSC lines such as RUES2, which has a doubling time of ~9 h, add fresh hPSC medium on the day of passaging hPSCs, and wait for at least 2 h before digesting the cells with Accutase/EDTA. Right before passaging the cells, eliminate prematurely differentiated colonies in hPSC cultures carefully with a 10-or 20-µl pipette tip (there should be very few or none
for well-maintained hPSC lines).  crItIcal Proper hPSC maintenance is crucial for subsequent DE induction. The feeder-to-hPSC ratio (not only the absolute density of feeders) is one of the key factors for proper hPSC maintenance, and it needs to be optimized for each hPSC line. Too high a ratio causes differentiation (morphological changes), and too low a ratio reduces the capacity of DE specification without noticeable morphological changes (see above for a range of ratios for tested lines). It is recommended to use low-passage-number (<3) feeder cells. If the DE induction efficiency gradually decreases over sequential passages for a specific cell line, it is worthwhile to verify the hPSC maintenance method. FGF-2 Reconstitute FGF-2 in sterile PBS + 0.1% (wt/vol) final concentration of BSA to obtain a 20 µg/ml solution. Make 1-ml aliquots and store them at −20 °C for up to 6 months.  crItIcal Thaw all the cytokines only once. Store thawed aliquots at 4 °C for up to 1 month.
Y-27632
Reconstitute ROCK inhibitor Y-27632 in DMSO to obtain a 10 mM solution. Make 100-µl aliquots and store them at −20 °C for up to 1 year. Ascorbic acid solution, 50 mg/ml Prepare a 50 mg/ml ascorbic acid solution by dissolving 500 mg of l-ascorbic acid powder in 10 ml of water, and then filter it with a 0.22-µM Steriflip-GP filter. Make 100-µl aliquots and store them at 20 °C for up to 6 months. Store thawed aliquots at 4 °C and use them within 24 h. DNase I Reconstitute DNase I by dissolving 10 MU (~167 mg) of lyophilized powder in 167 ml of sterile water to obtain a 1 mg/ml (10×) stock solution. Make 1-ml aliquots and store them at −20 °C for up to a year. Further dilute 10× stock with sterile PBS to obtain a 1 µg/ml solution. Make 1,000-µl aliquots and store them at −20 °C for up to 1 year. Activin A Reconstitute activin A in sterile PBS + 0.1% (wt/vol) final concentration of BSA to obtain a 100 µg/ml solution. Make 100-µl aliquots and store them at −20 °C for up to 6 months. Wnt3A Reconstitute Wnt3A in sterile PBS + 0.1% (wt/vol) final concentration of BSA to obtain a 100 µg/ml solution. Make 100-µl aliquots and store them at −20 °C for up to 6 months. Dorsomorphin dihydrochloride (DSM) Reconstitute DSM in DMSO to obtain a 2 mM solution. Make 100-µl aliquots and store them at −20 °C for up to a year. NOGGIN Reconstitute NOGGIN in sterile PBS + 0.1% (wt/vol) final concentration of BSA to obtain a 100 µg/ml solution. Make 100-µl aliquots and store them at −20 °C for up to 6 months.
SB-431542
Reconstitute SB-431542 in DMSO to obtain a 10 mM solution. Make 100-µl aliquots and store them at −20 °C for up to 1 year. IWP2 Reconstitute IWP2 in DMSO to obtain a 1 mM solution. Make 100-µl aliquots and store them at −20 °C for up to 1 year. CHIR99021 Reconstitute CHIR99021 in DMSO to obtain a 3 mM solution. Make 100-µl aliquots and store them at −20 °C for up to 1 year. FGF10 Reconstitute FGF10 in sterile PBS + 0.1% (wt/vol) final concentration of BSA to obtain a 10 µg/ml solution. Make 300-µl aliquots and store them at −20 °C for up to 6 months. FGF7 Reconstitute FGF7 in sterile PBS + 0.1% (wt/vol) final concentration of BSA to obtain a 10 µg/ml solution. Make 300-µl aliquots and store them at −20 °C for up to 6 months. hPSC maintenance medium Combine 400 ml of DMEM/F12, 100 ml of KnockOut serum replacement, 5 ml of GlutaMAX, 5 ml of MEM-non-essential amino acids, 3.5 µl of 2-mercaptoethanol and 1 ml of primocin to make a total of ~500 ml of medium. Filter the solution using a 0.22-µm pore size filter unit. This sterile medium can be stored at 2-8 °C for up to 1 month. Add FGF-2 to a final concentration of 20 ng/ml hPSC culture before use. MEF conditioned medium Prepare MEF conditioned medium (CM) by adding 1.2 ml per well of hPSC maintenance medium to a feeder plate without hPSCs. Ideally, CM is collected every 24 h from day 2-day 5 (d2-d5) feeder plates and stored at 4 °C; use it within 2 weeks. IMDM medium reconstitution Reconstitute IMDM medium by adding 1 pack of IMDM powder (17.7g) and 3.024 g of sodium bicarbonate to 1 liter of WFI cell culture grade water. Mix it well and filter the medium using a 0.22-µm pore size filter unit. This sterile medium can be stored at 2-8 °C for up to 1 month. Medium for MEFs Combine 425 ml of reconstituted IMDM, 75 ml of ESC-quality FBS, 20 µl of MTG, 5 ml of GlutaMAX and 5 ml of penicillin-streptomycin to make 500 ml of medium for MEFs. This sterile medium can be stored at 2-8 °C for up to 1 month. Wash medium Combine 500 ml of reconstituted IMDM, 25 ml of ESC-quality FBS, 5 ml of GlutaMAX and 5 ml of penicillin-streptomycin to make ~500 ml of wash medium. This sterile medium can be stored at 2-8 °C for up to 1 month. Stop medium Combine 100 ml of reconstituted IMDM, 100 ml of ESC-quality FBS, 2 ml of GlutaMAX and 2 ml of penicillin-streptomycin to make ~200 ml of medium; this sterile medium can be stored at 2-8 °C for up to 1 month. Add the appropriate amount of DNase I stock solution immediately before use only to the volume needed, to obtain complete stop medium with a final concentration of 30 ng/ml DNase I. Serum-free differentiation medium For ~1 liter of serum-free differentiation (SFD) medium, combine 750 ml of reconstituted IMDM, 250 ml of F-12, 7.5 ml of BSA, 10 ml of GlutaMAX, 5 ml of N2, 10 ml of B27 and 10 ml of penicillin-streptomycin. This sterile medium can be stored at 2-8 °C for up to 1 month. On the day of use, make fresh SFD + medium by adding l-ascorbic acid and MTG to obtain a final concentration of 50 µg/ml l-ascorbic acid and 0.04 µl/ml MTG, respectively. d0 medium (primitive streak formation) Add 1 µl/ml ROCK inhibitor stock, 0.1 µl/ml Wnt3a stock and 0.3 µl/ml BMP4 stock to SFD + medium to obtain a final concentration of 10 µM ROCK inhibitor, 10 ng/ml Wnt3a and 3 ng/ml BMP4, respectively. Freshly prepare the medium. d1-3 medium (DE induction) Add 1 µl/ml ROCK inhibitor stock, 1 µl/ml activin A stock, 0.05 µl/ml BMP4 stock and 0.25 µl/ml FGF-2 to SFD + medium to obtain a final concentration of 10 µM ROCK inhibitor, 100 ng/ml activin A, 0.5 ng/ml BMP4 and 2.5 ng/ml FGF-2, respectively. Freshly prepare the medium. d4/4.5/5 medium (AFE induction) Add 0.75-1 µl/ml DSM stock (as replace of 1 µl/ml NOGGIN) and 1 µl/ml SB431542 stock to SFD + medium to obtain a final concentration of 1.5-2 µM DSM (equivalent to 100 ng/ml of NOGGIN) and 10 µM SB431542, respectively. Freshly prepare the medium. d5/5.5/6 medium (AFE induction) Add 1 µl/ml IWP2 stock and 1 µl/ml SB431542 stock to SFD + medium to obtain a final concentration of 1 µM IWP2 and 10 µM SB431542, respectively. Freshly prepare the medium. d6/6.5/7-d15 medium Add 1 µl/ml CHIR99021 stock, 1 µl/ml KGF stock, 1 µl/ml FGF10 stock, 1 µl/ml BMP4 stock, 2 µl/ml EGF stock (optional) and 0.1 µl/ml retinoic acid stock to SFD + medium to obtain a final concentration of 3 µM CHIR99021, 10 ng/ml KGF, 10 ng/ml FGF10, 10 ng/ml BMP4, 20 ng/ml EGF (optional) and 50 nM retinoic acid, respectively. Freshly prepare the medium. d16-d25 medium Add 1 µl/ml CHIR99021 stock, 1 µl/ml KGF stock and 1 µl/ml FGF10 stock to SFD + medium to obtain a final concentration of 3 µM CHIR99021, 10 ng/ml KGF and 10 ng/ml FGF10, respectively. Freshly prepare the medium. d26 medium Add 1 µl/ml CHIR99021 stock, 1 µl/ml KGF stock, 1 µl/ml FGF10 stock, 2.5 µl/ml dexamethasone stock, 1 µl/ml IBMX stock and 1 µl/ml cAMP stock to SFD + medium to obtain a final concentration of 3 µM CHIR99021, 10 ng/ml KGF, 10 ng/ml FGF10, 25 ng/ml dexamethasone, 0.1 mM IBMX and 0. 3| Day −1. Prewarm Accutase to 37 °C. Remove the medium from hPSC culture and add Accutase. Digest hPSC cultures in the incubator. Digest the cultures for 2-3 min for a near-confluent plate. Time varies depending on the density of the hPSC culture. Aspirate the Accutase and add the wash medium.
4|
Remove the cells gently with stem cell passaging tool, transfer it to a 15-ml conical tube and pellet it at 300g for 5 min at 4 °C.
5|
Remove the supernatant with suction, and resuspend the hPSC pellet in 50% fresh hPSC medium + 50% MEF CM. Pay attention to remove the residual wash medium stuck on the wall of the conical tube to avoid residual FBS contamination of the hPSC medium.
6|
Transfer hPSCs to Matrigel-coated plates after removing nonadhering Matrigel, and place them in 95% air/5% CO 2 incubator. hPSC lines are typically passaged from >75% confluent six-well plate (~6-9 million cells per plate) onto Matrigel-coated plates in a 1:2 or 1:3 ratio (i.e., two or three wells per Matrigel plate). The ideal condition to start a differentiation on the following day is to have a 75-90% confluent plate with expansion of distinct, flattened hESC colonies (Fig. 2) ; therefore, culture the plates overnight. Ideally, the cells are in the Matrigel-coated plate for <24 h. However, some lines may require >24 h to achieve this morphology. If so, reduce the initial plating ratio to 1:1 or 1:1.5, and move onto Step 7 as appropriate.
primitive streak induction • tIMInG 18-24 h 7| Day 0. Prepare d0 medium (see Reagent Setup).
8| Dissociate the hES cells from the Matrigel-coated plates with warm 0.05% (wt/vol) trypsin in the incubator for 1-1.5 min. Tap the plate on the side with medium force, rotate it and tap again; repeat this motion two or three times. The cells will visibly come off the plate rapidly. Add stop medium to halt the reaction. Cells should be in 3-10-cell clusters when they are visualized under the microscope. Transfer the cells to a conical tube. Add an excess of wash medium, and pellet at 300g for 5 min at 4 °C.
9|
Aspirate the supernatant. Gently resuspend the pellet in a small volume (~3 ml) of d0 medium using a 5-ml serological pipette without generating bubbles. Add more d0 medium up to 12 ml per 10-cm 2 Matrigel-coated plate, and place the cells in six-well low-attachment plate(s) to form embryoid bodies (EBs; 2 ml per well). Place the plates in a 5% O 2 /5% CO 2 incubator overnight.
De induction • tIMInG 3-4 d 10| Day 1. Prepare DE induction medium (see Reagent Setup).
11| Collect the EBs in a conical tube, and add 1 ml per well of DE medium to the empty low-attachment plate(s) to avoid drying of the plate(s 19| Aspirate d5/5.5/6 medium and replace it with d6/6.5/7 medium. It is useful to spare a few wells without switching to lung induction medium to assess SOX2 and FOXA2 expression, evidence of appropriate AFE induction, by IF, for example, when you are optimizing the protocol for a new hPSC line. 
20|

23| Day 16. Prepare d16 medium (see Reagent Setup section).
24| Re-plating on day 16 . Collect and save the d15 medium from the culture plate (do a few wells at a time to avoid drying of the wells). Briefly digest it with warm (0.05%, wt/vol) trypsin for 1 min. Aspirate the trypsin and add the collected day 15 medium back to the wells. Mechanically detach the cells with 1,000-µl barrier tips and transfer them to a microcentrifuge tube (1-2 wells at a time) or a conical tube (multiple wells at a time). Pipette the medium up and down with medium force for a few times, and allow it to settle for a few minutes. Aspirate gently to remove the cloudy supernatant. Resuspend the clumps in d16 medium. Re-plate the cells into a new 0.33% (wt/vol) fibronectin-coated plate at a 1:3-1:5 ratio (depending on the cell line, initial confluence of the culture and whether the endpoint is d25 or d50).
Return the plates to the 5% O 2 /5% CO 2 tissue culture incubator.  crItIcal step This step is crucial for multiple reasons. First, in some lines, lung progenitor induction is not complete until ~d25. In these cases, re-plating is essential for post-d15 lung specification. Second, this step is crucial for removing non-endodermal cells in the culture. Typically, these cells are either neurectodermal cells or FOXA2 -P63 + NKX2.1 -SOX2 -EpCAM + PAX6 -PAX8 -cells whose identity is unclear 2 . Trypsin preferentially digests these into single cells or small cell clusters that stay in the supernatant and are removed by aspiration. Third, dissociation into single cells compromises viability compared with clump passaging. Viability can be improved by plating at confluent or overconfluent density, suggesting that the lung progenitors require close cell contact for survival. Furthermore, single-cell re-plating promotes the outgrowth of Tuj1 + neuronal cells.  pause poInt The clumps collected at this point can be frozen in DMEM + 10% DMSO + 50% FBS, and then thawed and plated onto 0.33% (vol/vol) fibronectin-coated tissue culture plates at later time points.
25| Culture for 10 additional days, changing the medium every second day (daily medium change might be necessary for confluent cultures). In general, it takes 4-6 d for the clumps to completely attach. In the first 4 d after re-plating, it might be necessary to manually remove the medium with pipette tips (instead of using vacuum suction) while changing the medium to avoid detaching the clumps. Collect the remaining suspension clumps (should be few), re-plate in a new 0.33% fibronectin-coated plate or redistribute back to the original plate. 
28|
Aspirate the medium, and replace it with d26 medium.
29|
Continue culturing for an additional 25 d to up to ~1 year, and change the medium every second day.
30|
At your preferred time points, perform RNA extraction and IF staining.
? trouBlesHootInG Troubleshooting advice can be found in table 2. (Fig. 3b,c, 
antIcIpateD results
Variability among hPSC differentiation potential is well documented. Cell line-dependent modifications include timing of DE dissociation (Fig. 3) , concentration of DSM/NOGGIN and of RA 2 . If all the steps are performed according to the procedures described above, with 'critical steps' taken into account, the purity of FOXA2 + SOX2 + NKX2.1 + PAX8 -lung progenitors at approximately day 15 of differentiation (Step 21) is expected to be ~80% or more for RUES2 (Fig. 4) and 30-60% or higher for most hiPSCs 2 (Fig. 3d,h ). For multiple hiPSC lines, however, FOXA2 + SOX2 + NKX2.1 + PAX8 -lung progenitor induction may not be complete at this stage (Step 21), and it reaches ~70-90% by approximately day 25 (Step 26) (Fig. 3e,i) . For lines such as RUES2, the induction is near 100% by approximately day 25 (Fig. 4b) .
At d25, FOXA2 + NKX2.1 + P63 + cells, a phenotype of putative basal cell precursors, are typically seen at the periphery of the clumps (supplementary Fig. 2) (Fig. 5) 2 . At this stage, the majority of the cells are FOXA2 + NKX2.1 + (Fig. 6a-c) , with a majority expressing SP-B (Fig. 6d-f) up to 3 months of further culture, a specific regional organization arises, with areas of proliferation surrounding areas where cells detach (Fig. 7) . Cells in these areas express the ATII marker, SP-B or coexpress SP-B and the ATI marker podoplanin (PDPN; table 1), suggestive of bipotential alveolar progenitors 29 or of ATII cells transitioning to an ATI fate (Fig. 7d,e) . In contrast, apoptosis occurs in areas with cells expressing airway markers, such as CC10 (table 1 and Fig. 7f) . Thus, the dynamics of the culture probably explain the predominance of cells expressing the ATII marker, SP-B, a population that includes a majority of SP-B + PDPN -cells and minority of SP-B + PDPN + cells; this phenotype was recently proposed to represent bipotential development alveolar progenitors 29 . 
